Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RVL PHARMACEUTICALS PLC

(RVLP)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
1.260 USD   -1.56%
01/30RVL Pharmaceuticals Files Shelf for Potential Sale of $200 Million Securities, Potential Resale of Shares by 2 Selling Shareholders
MT
01/09RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ« Net Product Sales
AQ
2022RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
1.34(c) 1.3(c) 1.31(c) 1.28(c) 1.26(c) Last
45 563 36 984 68 078 57 551 17 382 Volume
-3.60% -2.99% +0.77% -2.29% -1.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 52,3 M - -
Net income 2022 -49,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,30x
Yield 2022 -
Sales 2023 67,7 M - -
Net income 2023 -49,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,74x
Yield 2023 -
Capitalization 125 M 125 M -
Capi. / Sales 2022 2,39x
Capi. / Sales 2023 1,85x
Nbr of Employees 156
Free-Float 48,9%
More Financials
Company
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. The Company delivers RVL-1201 (Upneeq), (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, more commonly... 
Sector
Pharmaceuticals
Calendar
03/29Earnings Release
More about the company
Ratings of RVL Pharmaceuticals plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about RVL PHARMACEUTICALS PLC
01/30RVL Pharmaceuticals Files Shelf for Potential Sale of $200 Million Securities, Potentia..
MT
01/09RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% a..
AQ
2022RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophth..
AQ
2022Rvl Pharmaceuticals : Corporate Presentation November 2022
PU
2022RVL PHARMACEUTICALS PLC Management's Discussion and Analysis of Financial Condition an..
AQ
2022Transcript : RVL Pharmaceuticals plc, Q3 2022 Earnings Call, Nov 10, 2022
CI
2022Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q3 Revenue $10M
MT
2022RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commerci..
AQ
2022RVL Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months ..
CI
2022RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022
CI
2022RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Com..
AQ
2022Barclays Adjusts Price Target on RVL Pharmaceuticals to $3 From $4, Reiterates Overweig..
MT
2022Jefferies Assumes RVL Pharmaceuticals at Hold With $2.50 Price Target
MT
2022RVL Pharmaceuticals Expects 19% Sequential Increase in Upneeq Product Q3 Sales
MT
2022RVL Pharmaceuticals Expects 19% Sequential Increase in Upneeq Product Q3 Sales
MT
More news
News in other languages on RVL PHARMACEUTICALS PLC
01/30RVL Pharmaceuticals dépose un prospectus pour la vente potentielle de titres d'une vale..
2022RVL Pharmaceuticals plc annonce ses résultats pour le troisième trimestre et les neuf m..
2022RVL Pharmaceuticals plc réaffirme ses prévisions de ventes pour le quatrième trimestre ..
2022RVL Pharmaceuticals s'attend à une augmentation séquentielle de 19 % des ventes du prod..
2022RVL Pharmaceuticals s'attend à une augmentation séquentielle de 19 % des ventes du prod..
More news
Analyst Recommendations on RVL PHARMACEUTICALS PLC
More recommendations
ETFs positioned on RVL PHARMACEUTICALS PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.01%4.70%United_States
More ETFs positioned on RVL PHARMACEUTICALS PLC
Chart RVL PHARMACEUTICALS PLC
Duration : Period :
RVL Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RVL PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,26 $
Average target price 3,68 $
Spread / Average Target 192%
EPS Revisions
Managers and Directors
Brian A. Markison Chairman, Chief Executive & Financial Officer
Tina Devries Executive VP-Research & Development
James Schaub Chief Operating Officer & Executive Vice President
Sergio Alegre Vice President-Global Compliance
David Fredrick Burgstahler Independent Director
Sector and Competitors